Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04104776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04104776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 18, 2019
Completion date
February 27, 2030
Enrollment
300 (estimated)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, diffuse large b cell lymphoma, endometrial cancer, lymphoma, t-cell, mesothelioma, malignant, metastatic castration-resistant prostate cancer, ovarian clear cell carcinoma, prostatic neoplasms, castration-resistant